---
schema_version: "secwatch.filing_event.v1"
accession: "0001299130-24-000005"
form_type: "8-K"
ticker: "PACB"
cik: "0001299130"
company_name: "PACIFIC BIOSCIENCES OF CALIFORNIA, INC."
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:03:26.286195+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# PacBio reports record preliminary Q4 revenue $58.4M, up 113% YoY; Revio installed base 173

## Summary
- Preliminary full year 2023 revenue $200.5M, up 56% YoY; Q4 revenue $58.4M (+113% YoY).
- Shipped 44 Revio systems in Q4, total installed base 173; annualized pull-through ~$385K per system.
- Preliminary Q4 consumables revenue $18.9M (67% from Revio); instrument revenue $35.1M.
- Cash, equivalents, and investments $631M as of Dec 31, 2023.
- Reaffirms 40-50% annual revenue growth target through 2026, aiming for >$500M in 2026.

## SEC filing metadata
- accession: 0001299130-24-000005
- form_type: 8-K
- ticker: PACB
- cik: 0001299130
- company_name: PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1299130/000129913024000005/0001299130-24-000005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1299130/000129913024000005/pacb-20240108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001299130-24-000005
- JSON: https://secwatch.observer/filing/0001299130-24-000005.json
- Plain text: https://secwatch.observer/filing/0001299130-24-000005.txt

## Key facts
- Earnings Releases
  PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported the full year ended December 31, 2023 results: revenue $200.5 million. Guidance reaffirmed.
  - Period: the full year ended December 31, 2023
  - Revenue: $200.5 million
  - Guidance: reaffirmed
  - Result: preliminary results
  source text: announced preliminary unaudited revenue for the fourth quarter 2023 and full year 2023 of $58.4 million and $200.5 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1299130/000129913024000005/0001299130-24-000005-index.htm
- Earnings Releases
  PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported the fourth quarter ended December 31, 2023 results: revenue $58.4 million. Guidance reaffirmed.
  - Period: the fourth quarter ended December 31, 2023
  - Revenue: $58.4 million
  - Guidance: reaffirmed
  - Result: preliminary results
  source text: PacBio reported preliminary, unaudited revenue of approximately $58.4 million for its fourth quarter ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1299130/000129913024000005/0001299130-24-000005-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.